Objective: To determine the clinical efficacy of TACE with platinum versus anthracyclines for hepatocellular carcinoma (HCC) patients using a meta-analysis.
Methods: We conducted a systematic review of the literature in PubMed, Embase, and the Cochrane Library database to discover relevant randomized controlled trials (RCTs) and observational studies. Data on therapeutic response, adverse event and overall survival rate from studies that compared TACE with platinum versus anthracyclines for HCC patients was extracted for pooled estimation. Subgroup analysis was used if further investigation was needed. The Q statistic and the I index statistic were used to assess heterogeneity. Publication bias was evaluated using Egger's test.
Results: Four RCTs and seven observational studies containing 1405 patients were included in this meta-analysis. After comparing RCTs and observational studies separately, the pooled estimation results indicated that no significant difference existed between platinum and anthracyclines regarding therapeutic response, adverse event and overall survival rate. Furthermore, Egger's test revealed bias in pooled estimation of survival rate among RCTs.
Conclusions: Based on current results, we concluded that TACE with platinum revealed similar clinical efficacy compared with anthracyclines. And more relative studies in this field were expected in the future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijsu.2018.03.049 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Which is the best TACE agent for patients with different NLR hepatocellular carcinomas? A systematic review and network meta-analysis.
Heliyon
May 2024
Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016 China.
Background: Transarterial chemoembolization (TACE) is a common treatment for hepatocellular carcinoma (HCC), but the best therapeutic agent for TACE treatment has not been determined. The neutrophil/lymphocyte ratio (NLR) is a systemic immune system marker; however, the ability of the NLR to predict the prognosis of patients with HCC is unknown, and no studies have been conducted to determine the most appropriate TACE regimen for HCC patients with different NLRs.
Methods: The PubMed, Embase, Web of Science, and CNKI databases were searched through May 28, 2023.
Interventional Radiology Locoregional Therapies for Intrahepatic Cholangiocarcinoma.
Life (Basel)
February 2024
Department of Medical Imaging, Division of Interventional Radiology, University of Arizona Medical Center, Tucson, AZ 85712, USA.
Surgical resection remains the cornerstone of curative treatment for intrahepatic cholangiocarcinoma (iCCA), but this option is only available to a small percentage of patients. For patients with unresectable iCCA, systemic therapy with gemcitabine and platinum-based agents represents the mainstay of treatment; however, the armamentarium has grown to include targeted molecular therapies (e.g.
View Article and Find Full Text PDFRadioiodine-131-Labeled Theranostic Nanoparticles for Transarterial Radioembolization and Chemoembolization Combination Therapy of VX2 Liver Tumor.
Adv Healthc Mater
December 2023
Department of Nuclear Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Article Synopsis
- Interventional treatments like TACE and TARE target tumors directly through the blood supply, making them promising for nanomedicine applications in hepatocellular carcinoma (HCC) despite challenges like residual tumors leading to recurrence.
- A new type of multifunctional nanoparticles (I-BaGdF @PDA-CDDP NPs), created by combining a chemotherapy drug with a radioisotope, demonstrates potential effectiveness in laboratory tests against cancer cells.
- These nanoparticles can be used in conjunction with imaging techniques for real-time tracking, and initial results show that they reduce tumor metabolism and increase cancer cell death in a rabbit model.
TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial.
Eur Radiol
November 2022
Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, 87 Dingjiaqiao Road, Nanjing, 210009, China.
Objectives: To investigate the efficacy and safety of dicycloplatin as chemotherapeutic regimen in transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).
Methods: In this randomized, open-label, phase II trial, patients with unresectable HCC who were TACE treatment-naïve or experienced recurrence after surgical resection or ablation were enrolled at 7 centers in China from March 2019 to November 2019. Participants were randomly assigned (1:1:1) to receive TACE with chemotherapeutic regimen of dicycloplatin alone (group A1), dicycloplatin plus epirubicin (group A2), or epirubicin alone (group B).
What Is the Most Suitable Agent Combined With Apatinib for Transarterial Chemoembolization Treatment in Advanced Hepatocellular Carcinoma Patients? A Systematic Review and Network Meta-analysis.
Front Oncol
May 2022
Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
Purpose: Combined therapy with transarterial chemoembolization (TACE) and apatinib is superior in therapeutic effect compared with TACE alone in patients with hepatocellular carcinoma (HCC). To determine the most suitable agent combined with apatinib for TACE treatment, we did a systematic review and network meta-analysis.
Methods: Four electronic databases were searched from inception until November 2021.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!